Share on LinkedInShare on LinkedIn

ARTICLE · 20 JANUARY 2011

Biosimilars, "Bolar Exception" and Data Exclusivity Under Turkish Law

Biosimilars are defined under the Communiqué on Pricing of Medicinal Products for Human Use as medicines that (i) are similar to and hold the same strength with licensed original biological medicines, (ii) are used to treat the same diseases as the original product, and (iii) are not generic.

TurkeyIntellectual Property
Duygu Aytaç
Duygu Aytaç

Biosimilars are defined under the Communiqué on Pricing of Medicinal Products for Human Use1 as medicines that (i) are similar to and hold the same strength with licensed original biological medicines, (ii) are used to treat the same diseases as the original product, and (iii) are not generic.

In line with this definition, the Guidelines on Biosimilar Medicinal Products2 describes biosimilars as "(...) medicines that are similar to a licensed and original biological medicine. The active ingredients of biosimilar products are similar to those of original biological medicines. Biosimilars and biological reference medicines usually have the same strength, and are used to treat the same diseases. Biosimilar medicines are only different from original biological medicines in terms of commercial name, appearance and packaging."

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from